Bokf Na Cuts Stock Position in Exact Sciences Co. (NASDAQ:EXAS)

BOKF NA cut its stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 35.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,481 shares of the medical research company's stock after selling 10,802 shares during the period. BOKF NA's holdings in Exact Sciences were worth $1,101,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the stock. Capital World Investors grew its holdings in shares of Exact Sciences by 10.7% during the fourth quarter. Capital World Investors now owns 17,537,617 shares of the medical research company's stock valued at $985,439,000 after buying an additional 1,696,321 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Exact Sciences by 74.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,760,241 shares of the medical research company's stock valued at $323,669,000 after buying an additional 2,462,165 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in shares of Exact Sciences by 25.8% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,269,823 shares of the medical research company's stock valued at $239,922,000 after buying an additional 876,985 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Exact Sciences by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 3,122,798 shares of the medical research company's stock valued at $175,165,000 after purchasing an additional 16,828 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Exact Sciences by 3.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,330,939 shares of the medical research company's stock valued at $74,785,000 after purchasing an additional 38,849 shares during the period. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Exact Sciences Trading Down 2.6%

NASDAQ:EXAS traded down $1.42 during trading hours on Wednesday, hitting $52.25. The company had a trading volume of 889,813 shares, compared to its average volume of 2,589,350. Exact Sciences Co. has a 1 year low of $39.97 and a 1 year high of $72.83. The company has a market cap of $9.86 billion, a P/E ratio of -9.38 and a beta of 0.92. The company has a 50-day moving average of $45.78 and a 200 day moving average of $52.49. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.16. The firm had revenue of $706.79 million during the quarter, compared to analysts' expectations of $688.58 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. Exact Sciences's revenue was up 10.9% compared to the same quarter last year. During the same period last year, the business earned ($0.60) earnings per share. Sell-side analysts expect that Exact Sciences Co. will post -0.58 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Robert W. Baird increased their price objective on Exact Sciences from $69.00 to $72.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Royal Bank of Canada raised their price target on shares of Exact Sciences from $52.00 to $54.00 and gave the stock a "sector perform" rating in a research report on Friday, May 2nd. William Blair restated an "outperform" rating on shares of Exact Sciences in a research report on Thursday, February 20th. Mizuho assumed coverage on shares of Exact Sciences in a research report on Thursday, April 10th. They set an "outperform" rating and a $60.00 target price for the company. Finally, Evercore ISI boosted their target price on shares of Exact Sciences from $60.00 to $66.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Two research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Exact Sciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $70.90.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.